Institute Oftalmologia Conde Of Valenciana

Conde, Mexico

Institute Oftalmologia Conde Of Valenciana

Conde, Mexico
SEARCH FILTERS
Time filter
Source Type

Serna-Ojeda J.C.,Institute Oftalmologia Conde Of Valenciana | Pedroza-Seres M.,Institute Oftalmologia Conde Of Valenciana
Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) | Year: 2016

The Vogt-Koyanagi-Harada syndrome is a disease with dermatological, neurologic and auditory findings, associated with a bilateral granulomatous panuveitis. We present the case of a 42-year-old woman who started with ophthalmic manifestations, and in a late follow-up she developed the characteristic dermatological findings.


Albavera-Giles T.,Institute Oftalmologia Conde Of Valenciana | Serna-Ojeda J.C.,Institute Oftalmologia Conde Of Valenciana | Jimenez-Corona A.,Institute Oftalmologia Conde Of Valenciana | Pedroza-Seres M.,Institute Oftalmologia Conde Of Valenciana
Graefe's Archive for Clinical and Experimental Ophthalmology | Year: 2017

Background: The purpose of this study was to evaluate the characteristics and outcomes of cataract surgery with/without vitrectomy in patients with pars planitis who received immunosuppressive therapy. Methods: This was a retrospective case series, single-center study. Twenty-two patients with pars planitis who received immunosuppressive therapy were included, with a median age at presentation of 9.5 years, having had cataract surgery. The following data was collected: age at presentation and at cataract surgery, time of follow-up, best-corrected visual acuity (BCVA) before the surgery and at 1 week, 1 and 6 months after the procedure, immunosuppressive therapy, complications and causes for failed visual improvement. The variables associated with an improvement in visual acuity were evaluated. Results: All patients had phacoemulsification with intraocular lens implantation. The most common immunosuppressive therapy used for the patients was methotrexate in nine patients (40.9%). The BCVA improved from a median of 20/400 to 20/100 after 6 months of follow-up (p = 0.0005); 14 patients (63.6%) improved two lines of vision or more. No significant risk factors were found for the association with improvement in visual acuity after the surgery. No improvement in visual acuity was attributed to posterior segment manifestations or amblyopia; the most common complication was posterior capsule opacification in 11 eyes (50%). The median follow-up after the surgery was 32 months. Conclusion: Phacoemulsification was the procedure for all the patients. Visual acuity improved in patients with pars planitis treated with immunosuppressive drugs who underwent cataract surgery, except for the patients with posterior segment complications or amblyopia. © 2017 Springer-Verlag Berlin Heidelberg


Chacon-Camacho O.F.,Institute Oftalmologia Conde Of Valenciana | Zenteno J.C.,Institute Oftalmologia Conde Of Valenciana | Zenteno J.C.,National Autonomous University of Mexico
Gaceta Medica de Mexico | Year: 2017

This is a significant time moment in the field of gene therapy in humans. Recently, results from a phase III clinical trial were published, demonstrating the first gene therapy success for a genetic disease. A clinical trial was carried out in patients suffering a hereditary blindness disease named Leber congenital amaurosis, caused by mutations in the RPE65 gene. Participating subjects received a subretinal injection of the normal RPE65 gene and one year after exhibited a significant improvement in visual acuity. It is expected that this gene therapy treatment will be approved by the FDA and commercialized in the USA in 2017. © 2017, Academia Nacional de Medicina, All rights reserved.


Oliva-Bienzobas V.,Institute Oftalmologia Conde Of Valenciana
Cornea | Year: 2017

PURPOSE:: To report a mutation of CYP1B1 in a newborn with a rare phenotype without the classic features of anterior segment dysgenesis or congenital glaucoma. METHODS:: The newborn presented with diffuse corneal edema and bilaterally elevated intraocular pressure (IOP). Ophthalmological examination, ultrasound, and ultrasound biomicroscopy were performed; congenital infections were ruled out. Genetic analysis was performed. The patient underwent penetrating keratoplasty and goniotomy in a single surgical time. The button was subjected to histopathological examination. RESULTS:: The patient is the first child of young, healthy, consanguineous parents. Ophthalmological examination revealed visual acuity of light perception and increased IOP in both eyes. CYP1B1 gene analysis demonstrated homozygosity for a 1-bp deletion in exon 2 (c.830delT). IOP was normalized, and the corneal button was clear after surgical treatment. Histopathological analysis revealed loss of the Bowman membrane in the central cornea, fibrosis of the stroma, absence of endothelial cells, and loss of Descemet membrane centrally. CONCLUSIONS:: We present an uncommon mutation and clinical description of CYP1B1. This report and further studies could provide us better understanding of the mutational spectrum of CYP1B1. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.


Garcia-Lopez A.,Fundacion Hospital Of Nuestra Senora Of La Luz | Paczka J.A.,University of Guadalajara | Jimenez-Roman J.,Asociacion Para Evitar La Ceguera En Mexico Apec Hospital Dr Luis Sanchez Bulnes | Hartleben C.,Institute Oftalmologia Conde Of Valenciana
BMC Ophthalmology | Year: 2015

Background: Fixed-combination ocular hypotensives have multiple advantages, but triple-therapy dorzolamide/brimonidine/timolol (dorz/brim/tim) is only available in Latin and South America, and information on its relative efficacy is limited. This study compares the efficacy and tolerability of fixed-combination bimatoprost/timolol (bim/tim) and dorz/brim/tim in Mexican patients with primary open-angle glaucoma or ocular hypertension. Methods: In this investigator-masked, crossover study, patients with unmet target intraocular pressure (IOP) on once-daily bim/tim or twice-daily dorz/brim/tim received the opposite medication for 3 months before returning to their pre-baseline medication for 3 months. IOP was evaluated before and after morning instillation at months 2, 3, 5 and 6. Primary endpoints were mean IOP change and Ocular Surface Disease Index © (OSDI) score at each visit. The intent-to-treat population was the a priori analysis population, but due to the number of discontinuations, the per-protocol and intent-to-treat populations were used for the primary efficacy and sensitivity analyses, respectively. Results: Seventy-eight and 56 patients were included in the intent-to-treat and per-protocol populations, respectively. At month 3, statistically significant IOP reductions from baseline were observed in the bim/tim (P < 0.01) and dorz/brim/tim (P < 0.0001) groups, regardless of assessment time. At month 6, patients returned to bim/tim exhibited no significant IOP increase (regardless of assessment time), but patients returned to dorz/brim/tim exhibited a statistically significant IOP increase (P < 0.001) when assessed before instillation of study treatment. Results were similar in both intent-to-treat and per-protocol analysis populations. In the per-protocol analysis, 70% of patients on bim/tim at month 3 had an IOP <14 mm Hg, which declined to 58% (P = 0.0061) at month 6 (ie, after 3 months of dorz/brim/tim treatment). In patients receiving dorz/brim/tim at month 3, 38% had an IOP <14 mm Hg, which remained comparable after return to bim/tim. OSDI scores and incidence of adverse events were similar in both groups. Conclusions: In this first direct comparison of the efficacy of dorz/brim/tim and bim/tim, patients switched from dorz/brim/tim to bim/tim demonstrated improved/lower IOP; when returned to dorz/brim/tim, IOP increased to levels seen at study initiation, suggesting that once-daily bim/tim may have greater IOP-lowering efficacy. Both bim/tim and dorz/brim/tim were well tolerated with minimal ocular surface damage. © 2014 García-López et al.; licensee BioMed Central.


Abdala-Figuerola A.,Institute Oftalmologia Conde Of Valenciana
Cornea | Year: 2016

PURPOSE:: To report a case series of 7 eyes of 6 patients with posterior keratoconus, evaluating corneal Scheimpflug tomographic changes and anterior-segment optical coherence tomography (OCT). METHODS:: In our descriptive study, 6 patients were diagnosed with posterior keratoconus: 5 unilateral (7-, 33-, and 42-year-old males and 64- and 60-year-old female) and 1 bilateral (45-year-old female). Patients were diagnosed with slit-lamp examination, which revealed corneal opacity with an underlying posterior corneal depression. Additional analysis with anterior-segment OCT and Scheimpflug tomography evaluation was performed. RESULTS:: Localized paracentral posterior keratoconus was diagnosed in 7 eyes. Scheimpflug images demonstrated posterior corneal depression. Clinical findings were examined by OCT. Genetic analysis revealed no alterations or associated syndromes. All patients were amblyopic in the affected eye, and no surgery was offered to improve their visual acuity. CONCLUSIONS:: Posterior keratoconus is a rare noninflammatory condition usually present at birth and sometimes related to developmental abnormalities. Posterior keratoconus is usually unilateral and can present as a generalized or localized change in posterior corneal curvature. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.


Serna-Ojeda J.C.,Institute Oftalmologia Conde Of Valenciana | Pedroza-Seres M.,Institute Oftalmologia Conde Of Valenciana
British Journal of Ophthalmology | Year: 2014

Aim: To evaluate the clinical course of the patients with pars planitis that received immunosuppressive drugs. Methods: We retrospectively analysed the data of 10 years from 374 patients with pars planitis in a large reference centre in Mexico City and included 49 patients (92 eyes). Results: Median age at presentation was 8 years. 35 patients (71.4%) were male and 43 patients (87.7%) had bilateral disease. Diverse immunosuppressive medications were used, mainly methotrexate (69.4%) and azathioprine (63.3%) with 18 patients requiring more than one drug. The main indications for starting immunosuppressive therapy were lack of response to initial treatment and advance disease at presentation. The results showed good response with steroid reduction (69.3% of patients), visual acuity improvement (51% of patients) and inflammatory disease reduction (59.1% of patients). In 25 patients (51%), steroids were started previous to immunosuppressors and in 24 (49%) at the same time without significant difference in clinical improvement (p=0.210) or visual outcome ( p=0.498). Thirteen patients (26.5%) presented mild adverse effects. The median of the final visual acuity was 20/40. The median follow-up time was 44 months (range 13-115 months). Conclusions: Immunosuppressive therapy allows an adequate control of inflammatory disease in pars planitis, with clinical and visual improvement and steroid dose reduction.


Recillas-Gispert C.,Instituto Nacional Of Ciencias Medicas Y Nutricion Salvador Zubiran | Serna-Ojeda J.C.,Institute Oftalmologia Conde Of Valenciana | Flores-Suarez L.F.,systemIC
Graefe's Archive for Clinical and Experimental Ophthalmology | Year: 2015

Purpose: The purpose of this descriptive study was to evaluate the clinical response to rituximab (RTX) in patients with scleritis due to granulomatosis with polyangiitis (GPA), in patients who had proved refractory to treatment with systemic glucocorticoids and immunosuppressive agents. Methods: Retrospective analysis of interventional case series. Single referral center study. Eight patients (12 affected eyes) due to scleritis secondary to GPA, refractory to conventional treatment were included to receive RTX as therapy for remission induction. RTX was administered as a 1-g infusion every 2 weeks, for a total of 2 g. Patient follow-up included clinical evaluation (systemic and ophthalmologic), B-cell subset (CD19, CD20, CD22) counts, proteinase-3 anti-neutrophil cytoplasmic antibody (PR-3 ANCA), and Birmingham Vasculitis Activity Score for Wegener's granulomatosis (BVAS-WG). Outcomes were response to treatment and achievement of remission, as well as number of ocular relapses. Results: The main indication for treatment was refractory necrotising anterior scleritis. Four weeks after completion of treatment with RTX, all patients showed clear clinical improvement, with no further progression. In all patients, an absolute depletion of B cells was confirmed in the first 6 weeks after treatment. Seven patients (87.5 %) achieved remission of inflammatory activity in 7 months or less. However, three patients experienced ocular relapse, which comprised reactivation of the anterior scleritis, uveitis, and posterior scleritis, and two patients required a second dose of RTX, with immediate improvement. Conclusions: RTX is useful in the treatment of refractory necrotising scleritis in patients with GPA. Of note, in those who relapse after remission, RTX can be successfully used for retreatment. © 2015, Springer-Verlag Berlin Heidelberg.


Graue-Hernandez E.O.,Institute Oftalmologia Conde Of Valenciana | Pagano G.L.,Institute Oftalmologia Conde Of Valenciana | Garcia-De La Rosa G.,Institute Oftalmologia Conde Of Valenciana | Ramirez-Miranda A.,Institute Oftalmologia Conde Of Valenciana | And 4 more authors.
Journal of Cataract and Refractive Surgery | Year: 2015

Purpose To report visual, refractive, and topographic outcomes of sequential, same-day small-incision lenticule extraction and intrastromal corneal collagen crosslinking (CXL) in eyes with mild keratoconus. Setting Institute of Ophthalmology Conde de Valenciana, Mexico City, Mexico. Design Prospective interventional case series. Methods Fifteen eyes with forme fruste keratoconus and/or irregular corneas, corrected distance visual acuity 20/40 or better, stable refraction of at least 1 year, age 18 years or older, and residual corneal thickness of greater tan 400 μm before performing collagen crosslinking were studied. Patients were treated with small-incision lenticule extraction followed by intrastromal injection of riboflavin inside the pocket. Ultraviolet A light with a wavelength of 370 nm to 3 mW/cm2 was applied for 30 minutes. Follow-up was done at 1 day, at 1 week, and at 1, 3, 6, 12, 18, and 24 months. Results Eight patients were included in the study. The mean age was 29.5 years ± 5.5 (SD) (range 20 to 36 years). Twenty-four months of follow-up were completed in 13 eyes, and 12 months were completed in 2 eyes. Preoperative uncorrected distance visual acuity improved from 1.6 ± 0.3 LogMAR (Snellen 20/796) to postoperative 0.12 ± 0.20 LogMAR (Snellen 20/26) and was statistically significant (P <.001). Best-corrected distance visual acuity did not change significantly (P =.186), from 0.006 ± 0.02 LogMAR (Snellen 20/20) preoperatively to 0.04 ± 0.05 LogMAR (Snellen 20/21) postoperatively, and spherical equivalent improved from -4.3 ± 1.02 preoperatively to 0.2 ± 0.66 (P <.001). Conclusion Although further follow-up and larger samples are needed to fully confirm these findings, the results suggest that combined small-incision lenticule extraction and intrastromal corneal collagen crosslinking are a promising treatment option for patients for whom conventional laser refractive surgery is contraindicated. © 2015 The Authors.


Hernandez-Camarena J.C.,Institute Oftalmologia Conde Of Valenciana | Chirinos-Saldana P.,Institute Oftalmologia Conde Of Valenciana | Navas A.,Institute Oftalmologia Conde Of Valenciana | Ramirez-Miranda A.,Institute Oftalmologia Conde Of Valenciana | And 3 more authors.
Journal of Refractive Surgery | Year: 2014

PURPOSE: To assess the reliability of three different Scheimpflug systems and their agreement.METHODS: Eighty-four eyes of 42 patients were examined with three Scheimpflug devices: The Galilei G2 Dual Scheimpflug Analyzer (Ziemer Ophthalmic Systems AG, Port, Switzerland), Pentacam HR system (Oculus Optikger'te GmbH, Wetzlar, Germany), and Sirius 3D imaging system (Costruzione Strumenti Oftalmici, Florence, Italy). The central corneal thickness, maximum anterior and posterior corneal elevation, anterior radius of curvature, total higher-Order aberrations, and anterior chamber depth were evaluated. Repeatability and reproducibility were evaluated using coefficients of variation and intraclass correlation coefficients. Interdevice agreement was assessed by Bland'Altman comparison analysis.RESULTS: The three Scheimpflug systems had excellentrepeatability for central corneal thickness, anterior radius of curvature, and anterior chamber depth (coefficients of variation being less than 1%). Repeatability for anterior and posterior corneal evaluation was good for the Pentacam HR and Galilei G2 (coefficients of variation < 10%) and excellent for the Sirius 3D (coefficients of variation = 0). Reproducibility was excellent in the three devices, (intraclass correlation coefficient of more than 0.9). Interdevice agreement was excellent (P > .05) for anterior radius of curvature, central corneal thickness, and anterior chamber depth, but was poor (P < .05) for corneal elevation and higher-Order aberrations.CONCLUSIONS: Reliability was good to excellent in the three devices for all measured variables. Interdevice agreement analysis suggests that measurements for anterior radius of curvature, central corneal thickness, and anterior chamber depth, but not for maximum anterior and posterior corneal elevation and total higherorder aberrations, from the Sirius 3D and Galilei G2 can be interchangeable with the Pentacam HR. © SLACK Incorporated.

Loading Institute Oftalmologia Conde Of Valenciana collaborators
Loading Institute Oftalmologia Conde Of Valenciana collaborators